Porfimer sodium

Porfimer sodium
Clinical data
Trade names	Photofrin
AHFS/Drugs.com	Consumer Drug Information
License data	EU EMA: by INN; US FDA: Photofrin;
Routes of; administration	Intravenous
ATC code	L01XD01 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	NA
Protein binding	~90%
Elimination half-life	21.5 days (mean)
Excretion	Fecal
Identifiers
CAS Number	87806-31-3 ; ethyl ether: 97067-70-4 ;
PubChem CID	57166;
DrugBank	DB00707 ;
ChemSpider	10482283 ;
UNII	Y3834SIK5F; ethyl ether: 625J2HS54G ;
ChEMBL	ChEMBL1201707 ;
Chemical and physical data
Formula	C68H74N8O11 (for n=0)
Molar mass	1179.36 g/mol (for n=0) g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [Na+].CC(O)C1=C(C)C=2C=C5NC(=CC4=NC(=CC=3NC(C=C1N=2)=C(C)C=3CCC(O)=O)C(CCC(O)=O)=C4C)C(C)=C5C(C)OC(C)C6=C(C)C=7C=C%10NC(=CC9=NC(=CC=8NC(C=C6N=7)=C(C)C=8CCC(O)=O)C(CCC(O)=O)=C9C)C(C)=C%10C(C)O;
	InChI InChI=1S/C68H74N8O11.Na/c1-29-41(13-17-61(79)80)53-28-56-44(16-20-64(85)86)32(4)48(72-56)24-59-68(36(8)52(76-59)25-58-65(37(9)77)33(5)49(73-58)21-45(29)69-53)40(12)87-39(11)67-35(7)50-22-46-30(2)42(14-18-62(81)82)54(70-46)27-55-43(15-19-63(83)84)31(3)47(71-55)23-57-66(38(10)78)34(6)51(74-57)26-60(67)75-50;/h21-28,37-40,71-73,75,77-78H,13-20H2,1-12H3,(H,79,80)(H,81,82)(H,83,84)(H,85,86);/q;+1/b45-21-,46-22-,47-23-,48-24-,49-21-,50-22-,51-26-,52-25-,53-28-,54-27-,55-27-,56-28-,57-23-,58-25-,59-24-,60-26-; ; Key:CGQHMICGJYKFFJ-ZLJVSRBASA-N ;
	(what is this?) (verify)

Porfimer sodium, sold as Photofrin, is a photosensitizer used in photodynamic therapy and radiation therapy and for palliative treatment of obstructing endobronchial non-small cell lung carcinoma and obstructing esophageal cancer.

Porfimer is a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units.^[1] In practice, a red light source emitting at 630 nm is used to excite the Porfimer oligomers.^[2]

Porfimer is Haematoporphyrin Derivative (HpD) (See PDT).

Approvals and indications

It was approved in Canada in 1993 for the treatment of bladder cancer.^[2] It was approved in Japan in 1994 (for early stage lung cancer?).^[2] It was approved by the U.S. FDA in December 1995 for esophageal cancer, and in 1998, it was approved for the treatment of early non-small cell lung cancer.^[2]

In August 2003 the FDA approved its use for Barrett's esophagus.^[3]

References

^ "Porfimer injection Prescribing information" (PDF). Archived from the original (PDF) on October 16, 2012.
^ ^a ^b ^c ^d Usuda J, Kato H, Okunaka T, Furukawa K, Tsutsui H, Yamada K, et al. (June 2006). "Photodynamic therapy (PDT) for lung cancers". Journal of Thoracic Oncology. 1 (5): 489–93. doi:10.1016/S1556-0864(15)31616-6. PMID 17409904.
^ "FDA Patient Safety News: Show #20, October 2003". October 2003. Archived from the original on October 19, 2010. Retrieved 2009-08-17.

External links

[1] "Porfimer injection Prescribing information" (PDF). Archived from the original (PDF) on October 16, 2012.

[Usuda_2006-2] Usuda J, Kato H, Okunaka T, Furukawa K, Tsutsui H, Yamada K, et al. (June 2006). "Photodynamic therapy (PDT) for lung cancers". Journal of Thoracic Oncology. 1 (5): 489–93. doi:10.1016/S1556-0864(15)31616-6. PMID 17409904.

[3] "FDA Patient Safety News: Show #20, October 2003". October 2003. Archived from the original on October 19, 2010. Retrieved 2009-08-17.

[1]

[2]

[3]